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Epilepsy is a group of neurological syndromes 
characterized by the occurrence of recurrent spontaneous 
seizures [1]. These arise due to transient imbalances 
between excitation and inhibition in the brain and may 
have a genetic origin or are acquired as a result of an insult 
to the brain. Epileptogenesis is the process whereby the 
brain undergoes pathological changes which eventually 
lead to the emergence of spontaneous seizures. 
 Epileptogenesis is associated with large-scale 
changes in protein expression which contribute to 
hyperexcitability-promoting alterations in neuronal 
networks and synaptic transmission [2]. While most focus 
has understandably been on transcriptional changes there 
is growing evidence that turnover of proteins within cells, 
particularly locally, at synapses, plays a critical role. 
The ubiquitin proteasome system (UPS) is highly 
conserved among different species and is the principal 
intracellular pathway leading to the clearance of short-
lived, aberrant and/or misfolded proteins. The UPS 
consists of two separate steps including protein labeling 
via polyubiquitination and the subsequent degradation 
of polyubiquitinated proteins by the proteasome [3]. An 
impairment of the UPS has been proposed as a common 
pathological characteristic among acute and chronic 
brain diseases including ischemia, traumatic brain 
injury, neurodegenerative diseases and epilepsy [3-5]. 
Consequently, modulators of proteasome function have 
been postulated as a potential new treatment strategy for 
these diseases [3]. 
 Previous studies suggest UPS function is also 
altered in epilepsy and there is in vitro evidence that 
increased neuronal activity interferes with a correct 
functioning of the proteasome [6]. The immunoproteasome 
which plays an important role in the degradation of 
damaged proteins resulting from cytokine-stimulated 
protein synthesis during an inflammatory response or 
oxidative stress is also up-regulated in experimental 
epilepsy models and in the brain of epilepsy patients [5]. 
Whether UPS function is compromised during seizures 
in vivo, however, had not been explored. By using a 
UPS green-fluorescent protein (GFP)-reporter mouse we 
demonstrated that there is impairment of UPS function 
following prolonged seizures (status epilepticus) triggered 
by an injection of the excitotoxin kainic acid in mice. The 
UPS dysfunction persisted into the period when mice 
display recurrent spontaneous seizures [7]. However, the 
most striking finding was that UPS inhibition displayed 
sharp spatio-temporal changes as it evolved over time, 
being most evident in brain regions resistant to seizure-
induced cell death. The same response was found when 
seizures were triggered by another drug, pilocarpine, 
ruling out this being an artifact of the specific model. 
This prompted us to ask whether proteasome inhibition 
might provide neuroprotective effects. To test this idea 
we treated mice with a potent and selective inhibitor 
just before status epilepticus and showed that damage 
to the hippocampus could be reduced [7]. Although 
surprising, others have reported similar benefits of this 
class of drug in other models, including stroke [4]. The 
mechanism of the protection is currently unknown but 
may result from accumulation of proteins that mediate 
synaptic reorganization or neuroinflammatory signaling 
[4]. Evidence for a synaptic link was given a boost by the 
recent demonstration by our group that loss of ubiquitin 
carboxyl-terminal hydrolase isozyme L1 (UCHL1), 
deubiquitinating enzyme, occurs during status epilepticus 
and pharmacologic inhibition of the enzyme reduced 
levels of a key post-synaptic protein and aggravated 
seizures [8].
 There was another notable observation in our 
study. UPS impairment was first evident in the principal 
excitatory neurons of the hippocampus. However, UPS 
inhibition emerged in astrocytes at later stages [7]. We 
do not know why different cell populations undergo an 
impairment of the UPS at different time-points; however, 
it is tempting to speculate that this progression reflects 
specific metabolic or signaling changes that accompany 
responses to status epilepticus. Whereas neurons are 
recruited during acute seizures, astrocytes are activated 
during the inflammatory processes occurring at later 
disease stages. 
Several conclusions can be drawn from our studies. 
(1) An impairment of the UPS possibly contributes to 
changes in the proteome following seizures and during 
epilepsy. (ii) UPS inhibition is dependent on cell type and 
brain area affected. (iii) UPS inhibition may be beneficial 
at a certain range, (iv) seizures are a frequent co-morbidity 
among other brain diseases, therefore the observed UPS 
impairment in these diseases might be in part due to 
increased hyperexcitability states, and (v), finally, the 
identification of proteins showing a reduction in their 
UPS-dependent degradation during seizures might lead to 
the discovery of new drug targets for epilepsy.
 Our findings represent key steps in identifying the 
exact role the UPS carries out during seizures and epilepsy 
and helps point toward UPS-targeting drugs as potential 
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novel treatments for epilepsy. Several unanswered 
questions remain, critical to further determine the 
therapeutic potential of UPS interference during epilepsy. 
What are the molecules that accumulate during UPS 
inhibition after seizures and do these differ between acute 
and chronic stages? Second, proteasome inhibition was 
only effective at a specific dose. What is the exact dose 
window to protect the brain and when does it become 
neurotoxic? Last, does proteasome inhibition benefit or 
harm the epileptic brain?
In conclusion, inhibition of proteasome function 
may constitute an endogenous protective mechanism in 
the setting of prolonged seizures. While it is unlikely 
that UPS-interfering drugs will be used in the future to 
treat epilepsy, identifying proteins which are regulated by 
the proteasome during seizures may represent new drug 
targets to protect the brain from seizure-induced damage.
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